Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios
暂无分享,去创建一个
William J. Jagust | Kewei Chen | Susan M. Landau | Robert Koeppe | Eric M. Reiman | Allison Fero | Suzanne L. Baker | Mark Mintun | M. Mintun | W. Jagust | R. Koeppe | S. Landau | E. Reiman | Kewei Chen | S. Baker | Allison Fero
[1] L. Thurfjell,et al. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[2] Nick C Fox,et al. 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.
[3] John Seibyl,et al. Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction , 2015, NeuroImage.
[4] V. Narayan,et al. Optimizing regions-of-interest composites for capturing treatment effects on brain amyloid in clinical trials. , 2014, Journal of Alzheimer's disease : JAD.
[5] James Robert Brašić,et al. In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.
[6] M. Mintun,et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid , 2013, Annals of neurology.
[7] W. Jagust,et al. Association of lifetime cognitive engagement and low β-amyloid deposition. , 2012, Archives of neurology.
[8] Andrei G. Vlassenko,et al. Amyloid‐beta plaque growth in cognitively normal adults: Longitudinal [11C]Pittsburgh compound B data , 2011, Annals of neurology.
[9] Cindee M. Madison,et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. , 2009, Brain : a journal of neurology.
[10] C. Rowe,et al. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[11] M. Mintun,et al. Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.
[12] R. Petersen,et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.
[13] M. Mintun,et al. Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.
[14] H. Engler,et al. PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.
[15] E. Salmon,et al. 18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.
[16] R. Boellaard,et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[17] S. DeKosky,et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] R. Coleman,et al. Use of florbetapir-PET for imaging beta-amyloid pathology. , 2011, JAMA.
[19] Robert A. Dean,et al. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI , 2011, Acta Neuropathologica.